| Research Interests |
| 2008 - 2013 |
A Multi-center, Randomized, Double-blind, Placebo-controlled,
Phase 3 Study of Single-agent Tarceva® (erlotinib) Following
Complete Tumor Resection with or without Adjuvant Chemotherapy
in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma
who have EGFR-positive Tumors |
| |
|
| 2008 - 2010 |
Isolation and Characterization of Lung Cancer Stem Cells |
| |
|
| 2006 - 2011 |
A Randomized Phase III Study of Sublobar Resection versus
Subblolbar Resection Plus Brachytherapy in High Risk Patients
with Non-Small Cell Lung Cancer (NSCLC) 3cm. or Smaller: Z4032
|
| |
|
| 2004 - 2010 |
Use of Proteomic Analysis of Serum Samples for Detection of
Non-Small Cell Lung Cancer: Z4031 |
| |
|
| 2003 - 2009 |
A Prospective Study of the Prognostic Significance of Occult
Metastases in Patients with Resectable Non-Small Cell Lung Carcinoma
|
| |
|
| 2002 - 2010 |
Randomized Trial of Mediastinal Lymph Node Sampling vs. Complete
Lymphadenectomy During Pulmonary Resection in the Patient with
NO or N1 (Less Than Hilar) Non-Small Cell Carcinoma |
| |
|
| 2007 - 2012 |
A double-blind, randomized, placebo-controlled Phase III study
to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific
Cancer Immunotherapeutic as adjuvant therapy in patients with
resectable MAGE-A3-positive non-small cell lung cancer. |
| |
|
| 2006 - 2013 |
A Randomized, Double-blind Study to Evaluate the Safety and
Effectiveness of the Exhale® Drug-Eluting Stent in Homogeneous
Emphysema Subjects with Severe Hyperinflation |
| |
|
| 2003 - 2005 |
Respiratory muscle adaptations to COPD, VA hospital Philadelphia.
Stars and Strips Pilot Grant. |
| |
|
| 2001 - 2002 |
The use of functional genomic technology (micro arrays) to
improve the ability to diagnose malignant mesothelioma. McCabe
Fellow, University of Pennsylvania school of Medicine. |
| |
|
| 1994 - 1996 |
Therapeutic approaches and development of animal models for
the treatment of thoracic malignancies utilizing gene therapy,
antisense oligonucleotides, and immunotherapeutic approaches.
Advisor: Larry R. Kaiser, M.D., Thoracic Oncology Research Laboratory-Division
of Thoracic Surgery, University of Pennsylvania Medical Center. |
| |
|
| 1994 - 1996 |
Pre-clinical toxicity studies of intrathoracic recombinant
adenoviral gene therapy utilizing the HSV-thymidine kinase gene
in rodents and non-human primates. Proposal to the Food and
Drug Administration for a Phase I clinical trial. Advisor: Steven
M. Albelda, M.D., Thoracic Oncology Research Laboratory-Division
of Pulmonary and Critical Care Medicine, University of Pennsylvania
Medical Center. |
| |
|
| 1986 |
Development and evaluation of a centrifugal extraction
system to remove inhibitors from production grade monomer products.
Rohm and Haas Company Research and Development Campus, Springhouse,
Pennsylvania. |
